Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be ...

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive ...

The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...

When my bipolar depression returned, I mistakenly began to wean off a medication, not considering how it helped ease my other ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101.

but the treatment of bipolar depression varies substantially regionally. This group took as its mission to look at the available clinical evidence only. They did not take into account expert ...

Medication Side Effects and the Cost–Benefit ... Case in point: the continuing widespread use of antidepressants for bipolar depression, especially when not paired with a mood stabilizer.

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Some might argue that the management of bipolar depression with newer medications, such as lamotrigine or fluoxetine/olanzapine, is not that complicated and is well within the competence of many ...

Bipolar disorder is a complex psychiatric disorder, characterized by fluctuations between episodes of (hypo)mania and depression. Study published in ...

For decades, preclinical and clinical evidence has supported the effectiveness of thyroid hormone as an adjunctive treatment in adults living with bipolar depression, providing the basis for ...

PMDD symptoms align with the menstrual cycle, while bipolar disorder involves episodes of depression, mania, or hypomania that are not cycle-specific. Proper diagnosis and treatment can help ...